CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

Chemokine receptor CXCR4 overexpression in solid tumors has been strongly associated with poor prognosis and adverse clinical outcome. However, blockade of CXCL12-CXCR4 signaling axis by inhibitors like Nox-A12, FDA approved CXCR4 inhibitor drug AMD3100 have shown limited clinical success in cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Nengroo, Mushtaq A., Maheshwari, Shrankhla, Singh, Akhilesh, Verma, Ayushi, Arya, Rakesh K., Chaturvedi, Priyank, Saini, Krishan K., Singh, Anup K., Sinha, Abhipsa, Meena, Sanjeev, Gupta, Annapurna, Mishra, Anjali, Sarkar, Jayanta, Datta, Dipak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106681/
https://www.ncbi.nlm.nih.gov/pubmed/33966046
http://dx.doi.org/10.1038/s41419-021-03730-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106681/
https://www.ncbi.nlm.nih.gov/pubmed/33966046
http://dx.doi.org/10.1038/s41419-021-03730-8

Ejemplares similares